Meeting
2023 ASCO Annual Meeting
BrUOG 387: Phase Ib investigator-initiated trial of a heat shock protein 90 inhibitor (HSP90i) combined with a CDK4/6i in advanced breast cancer progressing on CDK4/6i and in solid tumors with retinoblastoma (Rb)-deficiency (IND163592).
Authors
Wafik S. El-Deiry
Legorreta Cancer Center at Brown University, Providence, RI
Wafik S. El-Deiry , Stephanie L. Graff , Christopher G. Azzoli , Don S. Dizon , Mary Anne Fenton , William M. Sikov , Howard Safran , Hina Khan , Humera Khurshid , Andrew Schumacher , Lanlan Zhou , Shuai Zhao , Attila A. Seyhan , Dinara Ryspayeva , Roxanne Wood , Arthur Winer , Elizabeth Martine Calleja , Eric A. Ross
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Small Molecules
Clinical Trial Registration Number
NCT05655598
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr TPS3167)
DOI
10.1200/JCO.2023.41.16_suppl.TPS3167
Abstract #
TPS3167
Poster Bd #
358a
Abstract Disclosures
Similar Posters
Poster
2021 Gastrointestinal Cancers Symposium
Phase II trial of the CDK4/6 inhibitor abemaciclib in patients (pts) with advanced and refractory well‐differentiated gastroenteropancreatic neuroendocrine tumors (GEP NETs).
First Author: Kit Man Wong
Poster
2023 ASCO Annual Meeting
A phase 3 study of gedatolisib plus fulvestrant with and without palbociclib in patients with HR+/ HER2- advanced breast cancer previously treated with a CDK4/6 inhibitor plus a nonsteroidal aromatase inhibitor (VIKTORIA-1).
First Author: Sara A. Hurvitz
Poster
2023 ASCO Annual Meeting
First-in-human first-in-class phase 1/2a study of the next generation CDK4-selective inhibitor PF-07220060 in patients (pts) with advanced solid tumors, enriched for HR+ HER2- mBC who progressed on prior CDK4/6 inhibitors and endocrine therapy.
First Author: Timothy A. Yap
Poster
2023 ASCO Annual Meeting
Real-world (RW) outcomes of patients (pts) with advanced breast cancer (aBC) with and without resistance alterations (alts) detected in cell-free circulating tumor DNA (ctDNA) prior to CDK4/6 inhibitor (CDK4/6i) plus endocrine therapy (ET) treatment.
First Author: Seth Andrew Wander